NEF PED - Artigos
Permanent URI for this collection
Browse
Browsing NEF PED - Artigos by Subject "Adolescent"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- Cefalea Crónica Diaria en Niños y AdolescentesPublication . Vieira, JP; Ferreira, AC; Veiga, E
- LAMA2 Gene Analysis in a Cohort of 26 Congenital Muscular Dystrophy PatientsPublication . Oliveira, J; Santos, R; Soares-Silva, I; Jorge, P; Vieira, E; Oliveira, ME; Moreira, A; Coelho, T; Ferreira, JC; Fonseca, MJ; Barbosa, C; Prats, J; Aríztegui, ML; Martins, ML; Moreno, T; Heinimann, K; Barbot, C; Pascual-Pascual, SI; Cabral, A; Fineza, I; Santos, M; Bronze-da-Rocha, ECongenital muscular dystrophy type 1A (MDC1A) is caused by mutations in the LAMA2 gene encoding laminin-alpha2. We describe the molecular study of 26 patients with clinical presentation, magnetic resonance imaging and/or laminin-alpha2 expression in muscle, compatible with MDC1A. The combination of full genomic sequencing and complementary DNA analysis led to the particularly high mutation detection rate of 96% (50/52 disease alleles). Besides 22 undocumented polymorphisms, 18 different mutations were identified in the course of this work, 14 of which were novel. In particular, we describe the first fully characterized gross deletion in the LAMA2 gene, encompassing exon 56 (c.7750-1713_7899-2153del), detected in 31% of the patients. The only two missense mutations detected were found in heterozygosity with nonsense or truncating mutations in the two patients with the milder clinical presentation and a partial reduction in muscle laminin-alpha2. Our results corroborate the previous few genotype/phenotype correlations in MDC1A and illustrate the importance of screening for gross rearrangements in the LAMA2 gene, which may be underestimated in the literature.
- Targeted Treatments for Myasthenia Gravis in Children and Adolescents.Publication . Ramdas, Sithara; Painho, Teresa; Vanegas, Maria I; Famili, Dennis T; Lim, Ming J; Jungbluth, HeinzMyasthenia gravis (MG) is an antibody-mediated disorder of the neuromuscular junction affecting children and adults. MG is a treatable condition with most patients requiring immunosuppression for disease control and/or remission. Juvenile myasthenia gravis (JMG) is rare in comparison with adult-onset MG but given the same underlying pathophysiology, treatment strategies are similar to those in adults. Until recently, there were only a few randomised controlled trials (RCTs) for MG treatments in adults and none in children, and management strategies were primarily based on expert consensus. In addition, treatment options for refractory MG cases have been severely limited, resulting in poor long-term quality of life in such patients due to the significant disease burden. Recently, there have been several RCTs focussing on novel therapeutic strategies with potentially promising outcomes, suggesting a change in MG management over the coming years and access to more effective and faster-acting drugs for MG patients. This paper will review current and new MG treatments including efgartigimod, eculizumab, rozanolixizumab, ravulizumab, and zilucoplan, with a focus on juvenile myasthenia gravis.